Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Sold by Nikko Asset Management Americas Inc.

Nikko Asset Management Americas Inc. decreased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 4.9% in the 4th quarter, HoldingsChannel reports. The firm owned 2,992,663 shares of the company’s stock after selling 155,734 shares during the quarter. Nikko Asset Management Americas Inc.’s holdings in Intellia Therapeutics were worth $34,894,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Commonwealth Equity Services LLC boosted its stake in shares of Intellia Therapeutics by 26.0% in the fourth quarter. Commonwealth Equity Services LLC now owns 30,764 shares of the company’s stock valued at $359,000 after purchasing an additional 6,343 shares during the period. Swiss National Bank boosted its stake in shares of Intellia Therapeutics by 6.0% in the fourth quarter. Swiss National Bank now owns 189,700 shares of the company’s stock valued at $2,212,000 after purchasing an additional 10,700 shares during the period. Wealthfront Advisers LLC purchased a new position in Intellia Therapeutics in the fourth quarter worth approximately $263,000. Regeneron Pharmaceuticals Inc. purchased a new position in Intellia Therapeutics in the fourth quarter worth approximately $43,177,000. Finally, Daiwa Securities Group Inc. lifted its stake in Intellia Therapeutics by 80.6% in the fourth quarter. Daiwa Securities Group Inc. now owns 5,151 shares of the company’s stock worth $60,000 after acquiring an additional 2,299 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Insider Buying and Selling at Intellia Therapeutics

In other news, CEO John M. Leonard sold 26,807 shares of the stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the sale, the chief executive officer now owns 941,115 shares in the company, valued at approximately $11,462,780.70. This represents a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 29,000 shares of company stock worth $352,551 over the last three months. Company insiders own 3.20% of the company’s stock.

Intellia Therapeutics Trading Down 0.9 %

Shares of NASDAQ NTLA opened at $9.14 on Monday. The business has a fifty day simple moving average of $10.36 and a 200 day simple moving average of $14.59. The firm has a market capitalization of $946.15 million, a price-to-earnings ratio of -1.68 and a beta of 1.97. Intellia Therapeutics, Inc. has a one year low of $8.30 and a one year high of $28.54.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Truist Financial reduced their price objective on shares of Intellia Therapeutics from $90.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, March 4th. Morgan Stanley lowered shares of Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $56.00 to $11.00 in a research report on Monday, January 27th. HC Wainwright assumed coverage on shares of Intellia Therapeutics in a research report on Wednesday, March 5th. They issued a “buy” rating and a $30.00 price objective on the stock. Oppenheimer reduced their target price on shares of Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating on the stock in a report on Monday, January 13th. Finally, Citigroup upped their price objective on shares of Intellia Therapeutics from $12.00 to $14.00 and gave the company a “neutral” rating in a research note on Friday, February 28th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $37.56.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.